Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
2. Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-n'-phenyl-
1. 1442472-39-0
2. Dcc-2618
3. N-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3- Yl]-2-fluorophenyl}-n'-phenylurea
4. Urea, N-[4-bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6- Naphthyridin-3-yl]-2-fluorophenyl]-n'-phenyl-39-0
5. Ripretinib Free Base
6. Ripretinib [usan]
7. Ripretinib (dcc-2618)
8. 9xw757o13d
9. Ripretinib (usan)
10. 1442472-39-0 (free Base)
11. 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
12. Qinlock
13. 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea
14. N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-n'-phenylurea
15. Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-n'-phenyl-
16. Quinlock
17. Qinlock (tn)
18. Ripretinib [mi]
19. Ripretinib [inn]
20. Ripretinib [who-dd]
21. Unii-9xw757o13d
22. Gtpl9175
23. Chembl4216467
24. Ripretinib [orange Book]
25. Schembl14999718
26. Dcc2618
27. Dtxsid201027956
28. Bcp29218
29. Ex-a4883
30. S8757
31. At18473
32. Db14840
33. Ac-36722
34. Hy-112306
35. Cs-0044835
36. D11353
37. Dcc 2618;dcc2618;kit/pdgfr Inhibitor;ripretinib
Molecular Weight | 510.4 g/mol |
---|---|
Molecular Formula | C24H21BrFN5O2 |
XLogP3 | 4.1 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 5 |
Exact Mass | 509.08627 g/mol |
Monoisotopic Mass | 509.08627 g/mol |
Topological Polar Surface Area | 86.4 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 746 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Ripretinib is indicated to treat adults diagnosed with advanced gastrointestinal stromal tumor (GIST) who have had prior therapy with at least 3 kinase inhibitors, including with [imatinib].
FDA Label
Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
As a broad-spectrum kinase inhibitor, ripretinib inhibits various gene mutations, increasing progression-free survival in patients with advanced gastrointestinal stromal tumors (GIST). It is effective in treating mutations that are resistant to chemotherapy with other kinase inhibitors, such as imatinib. Ripretinib has the propensity to cause cardiac dysfunction and new primary cutaneous malignancy. It is important to measure cardiac ejection fraction before and during treatment as well as to perform regular dermatological assessments.
L01
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EX - Other protein kinase inhibitors
L01EX19 - Ripretinib
Absorption
Ripretinib is absorbed in the gastrointestinal tract and Tmax is achieved in 4 hours, with steady-state concentrations reached within 14 days.
Route of Elimination
Ripretinib is 34% excreted in the feces and 0.2% excreted in the urine.
Volume of Distribution
The mean volume of distribution of ripretinib is 307 L.
Clearance
The mean apparent clearance of ripretinib is 15.3 L/hour.
Ripretinib is metabolized by the CYP3A subfamily of enzymes with contributions from CYP2D6 and CYP2E1 to its active metabolite, DP-5439.
The average half-life of ripretinib is 14.8 hours.
Protein kinases play important roles in cellular function, and their dysregulation can lead to carcinogenesis. Ripretinib inhibits protein kinases including wild type and mutant platelet-derived growth factor receptor A (PDGFRA) and KIT that cause the majority of gastrointestinal stromal tumor (GIST). In vitro, ripretinib has been shown to inhibit PDGFRB, BRAF, VEGF, and TIE2 genes. Ripretinib binds to KIT and PDGFRA receptors with mutations on the exons 9, 11, 13, 14, 17 and 18 (for KIT mutations), and exons 12, 14 and 18 (for PDGFRA mutations). The switch pocket of a protein kinase is normally bound to the activation loop, acting as an on-off switch of a kinase. Ripretinib boasts a unique dual mechanism of action of binding to the kinase switch pocket as well as the activation loop, thereby turning off the kinase and its ability to cause dysregulated cell growth.
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
79
PharmaCompass offers a list of Ripretinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ripretinib manufacturer or Ripretinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ripretinib manufacturer or Ripretinib supplier.
PharmaCompass also assists you with knowing the Ripretinib API Price utilized in the formulation of products. Ripretinib API Price is not always fixed or binding as the Ripretinib Price is obtained through a variety of data sources. The Ripretinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ripretinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ripretinib, including repackagers and relabelers. The FDA regulates Ripretinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ripretinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ripretinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ripretinib supplier is an individual or a company that provides Ripretinib active pharmaceutical ingredient (API) or Ripretinib finished formulations upon request. The Ripretinib suppliers may include Ripretinib API manufacturers, exporters, distributors and traders.
click here to find a list of Ripretinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ripretinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Ripretinib active pharmaceutical ingredient (API) in detail. Different forms of Ripretinib DMFs exist exist since differing nations have different regulations, such as Ripretinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ripretinib DMF submitted to regulatory agencies in the US is known as a USDMF. Ripretinib USDMF includes data on Ripretinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ripretinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ripretinib suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ripretinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ripretinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ripretinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ripretinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ripretinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ripretinib suppliers with NDC on PharmaCompass.
Ripretinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ripretinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ripretinib GMP manufacturer or Ripretinib GMP API supplier for your needs.
A Ripretinib CoA (Certificate of Analysis) is a formal document that attests to Ripretinib's compliance with Ripretinib specifications and serves as a tool for batch-level quality control.
Ripretinib CoA mostly includes findings from lab analyses of a specific batch. For each Ripretinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ripretinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Ripretinib EP), Ripretinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ripretinib USP).